[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Transforming Growth Factor Beta 1 - Pipeline Review, H1 2020

January 2020 | 88 pages | ID: TF394CE5A9BCEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Transforming Growth Factor Beta 1 - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2020'; Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 27 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

The report 'Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2020' outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Breast Cancer, Kidney Fibrosis, Osteoarthritis, Solid Tumor, Squamous Cell Carcinoma, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Cholangitis, Corneal Dystrophy, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hepatocellular Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Myelofibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar and Systemic Sclerosis (Scleroderma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
  • The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Avacta Life Sciences Ltd
Avellino Lab USA Inc
Bonac Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TGFB1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-1021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit TGFB1 for Corneal Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AlfaSigma SpA, H1 2020
Pipeline by Avacta Life Sciences Ltd, H1 2020
Pipeline by Avellino Lab USA Inc, H1 2020
Pipeline by Bonac Corp, H1 2020
Pipeline by Ensol Biosciences Inc, H1 2020
Pipeline by Forbius, H1 2020
Pipeline by Genzyme Corp, H1 2020
Pipeline by Huabo Biopharm Co Ltd, H1 2020
Pipeline by Isarna Therapeutics GmbH, H1 2020
Pipeline by Johnson & Johnson, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Phio Pharmaceuticals Corp, H1 2020
Pipeline by Scholar Rock Inc, H1 2020
Pipeline by Sirnaomics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AlfaSigma SpA
Avacta Life Sciences Ltd
Avellino Lab USA Inc
Bonac Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc


More Publications